Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]

Trials

Volumn 7, Issue , 2006, Pages

  Silva, Sandra Y ^a   Rueda, Ligia C ^a   López, Marcos ^b   Vélez, Iván D ^c   Rueda Clausen, Christian F ^a   Smith, Daniel J ^b   Muñoz, Gerardo ^d   Mosquera, Hernando ^a   Silva, Federico A ^a,d   Buitrago, Adriana ^a   Díaz, Holger ^e   López Jaramillo, Patricio ^a,f  

^a FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^b UNIVERSITY OF AKRON   (United States)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^e Programa de Chagas   (Colombia)

^f UNIVERSIDAD DE SANTANDER   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MEGLUMINE ANTIMONATE; NARCOTIC AGENT; NITRIC OXIDE DONOR; OXYGEN; PLACEBO;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BLOODY DIARRHEA; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EATING DISORDER; ELECTROLYTE DISTURBANCE; ENDEMIC DISEASE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MOUTH DISCOMFORT; MUSCLE DISEASE; MUSCLE NECROSIS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PARASITOLOGY; PATIENT PARTICIPATION; PHOTOGRAPHY; PRURITUS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REGISTER; REINFECTION; RESPIRATORY TRACT DISEASE; SKIN LEISHMANIASIS; SKIN ULCER; TRANSDERMAL PATCH; ULCER HEALING; URTICARIA; VOMITING;

EID: 33746776783     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-7-14     Document Type: Article

References (49)

1. S S, R S: Recent Advance in the diagnosis of Leishmaniasis. J Postgrad Med 2003, 49:55-60.
2. P D: Leishmaniasis: Public health aspects and control. Clin Dermatol 1996, 14:417-413.
3. Mandell: Principles and practice of infection diseases. 5th edition. Edited by: Elsevier. Churchill Livingstone, Inc.; 2000.
4. BL H: Leishmaniasis. Lancet 1999, 354:1191-1199.
5. RW A, P D, P R: Estimation of population at risk of infection and number of cases of Leishmaniasis. Parasitology Today 1992, 7:73-107.
6. Update: Cutaneous leishmaniasis in U.S. military personnel-Southwest/ Central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep 2004, 53:264-265.
7. CR D, R R, D CL, D F, R B, N R: The epidemiology and control of Leishmaniasis in Andean countries. Cad Saude Publica 2000, 16:925-950.
8. LA A, J U, D S, F R, ID V: Presence of American cutaneous Leishmaniasis vectors surrounding the city of Medellín, Colombia. Mem Inst Oswaldo Cruz 2002, 97:641-642.
9. NG S, I S, AF H, C S, L V, C O: Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 1998, 59:86-94.
10. W M, K M: Cutaneous Leishmaniasis: Recognition and treatment. Am Fam Physician 2004, 69:1455-1460.
11. L R, E H, S F: Leishmaniasis. BMJ 2000, 321:801-804.
12. G M, C D: Leishmania panamensis transmission in the domestic environment: the results of a prospective epidemiological survey in Santander, Colombia. Biomedica 2006, In press:.
13. NC H: Cutaneous Leishmaniasis: an overview. J Postgrad Med 2003, 49:50-54.
14. NC H, MJ T, JA H: Cutaneous Leishmaniasis in British troops from Belize. Br J Dermatol 1993, 128:63-68.
15. BL H, BA A, TR N: The natural history of cutaneous Leishmaniasis in Guatemala. J Infect Dis 1992, 165:518-527.
16. LE O, MC C, MT O: Mucosal Leishmaniasis due to Leishmania (viannia)panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg 1998, 59:49-52.
17. R P, LE O, LF G, MT O: Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous Leishmaniasis due to Leishmaniaviannia species. Am J Trop Med Hyg 2001, 64:187-193.
18. BL H, JD B: Recommendations for treating Leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992, 46:296-306.
19. J B, P D, E S, B B, C H: Treatment of cutaneous Leishmaniasis among travelers. J Antimicrob Chemother 2004, 53:158-166.
20. J S, P F, R H, J B: Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimotiate as treatment for american cutaneos leishmaniasis: Controlled Study. Clin Infect Disease 1998, 26:56-58.
21. EP H, SP A, DL M, JA P, ID V: Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in colombia. Am J Trop Med Hyg 1998, 59:889-892.
22. JD B: Leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997, 24:684-703.
23. MC F, MJ GM, F A, BR V, A C, AI A: Tratamiento de corta duración de la Leishmaniasis visceral con anfotericina B liposómica en pacientes inmunocompetentes. An Pediatr (Barc) 2003, 59:535-540.
24. RA S, J M, I M, J W, D N: Out-patient parenteral antimicrobial therapy-a viable option for the management of cutaneous Leishmaniasis. QJM 1999, 92:659-667.
25. J S, M G, J B, P O: Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous Leishmaniasis. Trans R Soc Trop Med Hyg 1994, 88:695-698.
26. J S, BA A, J T, N R, JC V, A D, P G, M A, JD B, K J, J E, H S: Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004, 38:1266-1272.
27. J S, J T, P G, M A, RS N, JR P, JD B, CK E, M G: Treatment of cutaneous Leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. J Trop Med Hyg 2002, 66:147-152.
28. A A, T J, JA W, RL G, M N, P O: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous Leishmaniasis in Iran. Am J Trop Med Hyg 1995, 53:648-651.
29. MA M, SE MG, KR G, M C, SL N, KA A, CJ B, N Y, BE B, ME W: Inducible resistance to oxidant stress in the protozoan Leishmaniachagasi. J Biol Chem 2000, 275:33883-33889.
30. M K: Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS 1997, 68:1-33.
31. A D, H S, M R, WM Y, C B: Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 1999, 284:951-955.
32. NL D, M F, E F, R R, IB M, FJ T: Nitric oxide and cellular immunity in experimental cutaneous Leishmaniasis. Clin Exp Dermatol 2003, 28:288-263.
33. K G, TL G, ML MC, MA M, S J, BE B, ME W: Oxidative Responses of Human and Murine Macrophages During Phagocytosis of Leishmania chagasi. J of Immunol 2001, 167:893-901.
34. M Q, I B, N D, M R, C B: Expression of inducible nitric oxide synthase in skin lesions of patients with american cutaneous Leishmaniasis. Infect Immun 2002, 70:4638-4642.
35. FY L, S M, C P, RM P, S M: Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990, 144:4794-4797.
36. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
37. I V, PA B, V RM, M A, O S, P D, D M, MD M: Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 1997, 27:860-865.
38. L P, CA OD, FY L: Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur J Immunol 1995, 25:745-750.
39. P LJ, C R, J R, E T, R SI, JV E, S M: Treatment of cutaneous Leishmaniasis with nitric-oxide donor. Lancet 1998, 351:1176-1177.
40. RN D, V Y, SL C, P K, N B: A topical nitric oxide-generating therapy for cutaneous Leishmaniasis. Trans R Soc Trop Med Hyg 2000, 94:319-322.
41. J D, DH R: Electrospinning process and applications of electrospun fibers. J of Electrostatics 1995, 35:151-160.
42. Kenawy ER, J L, JR W, GL B, JA M, DG S, GE W: Electrospinning of poly(ethylene-co-vinyl alcohol) fibers. Biomaterials 2003, 24:907-913.
43. Kenawy ER, GL B, K M, J L, DG S, EH S, GE W: Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release 2002, 81:57-64.
44. LM H, W K, DH R, DJ S: Production of superabsorbent electrospun nanofibers. Polymeric Materials Science and Engineering 2004, 90:508.
45. D S: Stabilization and ionic triggering of nitric oxide release. PCT Int Appl WO 2004-US23867 2004.
46. Vega-Lopez F: Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis 2003, 16:97-101.
47. Foreyt WJ: Diagnostic parasitology. Vet Clin North Am Small Anim Pract 1989, 19:979-1000.
48. Kar K: Serodiagnosis of leishmaniasis. Crit Rev Microbiol 1995, 21:123-152.
49. Grimaldi G, McMahon-Pratt D: Monoclonal antibodies for the identification of New World Leishmania species. Mem Inst Oswaldo Cruz 1996, 91:37-42.